Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population by Kim E Innes et al.
Innes et al. BMC Cancer 2014, 14:45
http://www.biomedcentral.com/1471-2407/14/45RESEARCH ARTICLE Open AccessInverse association of colorectal cancer
prevalence to serum levels of perfluorooctane
sulfonate (PFOS) and perfluorooctanoate (PFOA)
in a large Appalachian population
Kim E Innes1,2*, Jeffrey H Wimsatt3, Stephanie Frisbee4 and Alan M Ducatman5,6Abstract
Background: Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) are persistent environmental
contaminants that affect metabolic regulation, inflammation, and other factors implicated in the development and
progression of colorectal cancer (CRC). However, the link between these compounds and CRC remains unknown.
In this cross-sectional study, we investigated the association of CRC diagnosis to PFOA and PFOS blood levels in a
large Appalachian population.
Methods: Participants were 47,359 adults≥ 21 years of age and residing in six PFOA-contaminated water districts
in the mid-Ohio Valley (N = 47,151 cancer-free adults, 208 cases of primary CRC). All participants completed a
comprehensive health survey between 2005 and 2006; serum levels of PFOA, PFOS, and a range of other blood
markers were also measured. Medical history was assessed via self report and cancer diagnosis confirmed via chart
review.
Results: CRC showed a strong inverse, dose–response association with PFOS serum levels (odds ratio (OR) adjusted
for potential confounders = 0.2, 95% confidence interval (CI) 0.2,0.3) for highest vs. lowest quartile of PFOS,
P-trend < 0.00001) and a significant, but more modest inverse association with PFOA (adjusted OR = 0.6 (CI 0.4, 0.9)
for highest vs. lowest quartile, P-trend = 0.001). These inverse associations were stronger in those diagnosed within the
previous 6 years and resident in the same water district for a minimum of 10–15 years preceding assessment. The
relationship between PFOA and CRC was also more pronounced in men and leaner adults, and showed a stronger
linear trend at lower exposure levels.
Conclusions: In this large cross-sectional study, we found a strong, inverse association between PFOS and likelihood of
CRC diagnosis and a significant, although more modest inverse association between PFOA and CRC. If confirmed in
prospective investigations, these findings may aid in identifying new strategies for CRC prevention and treatment and
inform future studies regarding mechanisms underlying CRC pathogenesis.
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While incidence and mortality rates of colorectal cancer
(CRC) have declined during the past decade, CRC remains
the third most common cancer in both men and women
and the third leading cause of cancer-related mortality in
the United States [1,2]. Major risk factors for CRC include
age, a family or personal history of CRC, colorectal polyps,
chronic inflammatory bowel disease, and inherited genetic
alterations, such as familial adenomatous polyposis or her-
editary nonpolyposis CRC (Lynch syndrome) [2,3]. CRC
rates are higher in men and in African American popula-
tions [2,3]. Certain lifestyle-related factors also increase
risk for CRC, including physical inactivity, obesity, smok-
ing, and a diet high in red and processed meats [2,3].
Recent cohort studies suggest constipation may also
increase CRC risk [4,5]. Conversely, a growing body of
evidence suggests that use of aspirin and other anti-
inflammatory medications [6-9] and certain dietary supple-
ments (e.g., calcium) may be protective against CRC [2]. In
addition, the role of peroxisome proliferator-activated
receptor-γ (PPAR-γ) in adipocyte differentiation, the anti-
proliferative and/or differentiating effects of PPAR-α and
PPAR-γ ligands in human colon and other tumor cell lines,
and the anticancer effects of both PPAR isotypes in animal
models of CRC support a chemoprotective role for these
nuclear hormone receptors [10,11].
Certain environmental contaminants have also been
linked to increased risk for incident CRC, including drink-
ing water nitrate [12] and chloroform levels [13]. However,
the link between CRC and other widespread contaminants,
including perfluorocarbon compounds (PFC’s), remains
unclear [14,15]. Given the documented protective role of non-
steroidal anti-inflammatory medications [6], and the grow-
ing number of studies supporting a role for PPARs in CRC
prevention and treatment [10,11], it is possible that certain
perfluoroalkyl acids (PFAAs), including the widespread pol-
lutants, perfluoroctanoic acid (PFOA) and perfluorooctane-
sulfonic acid (PFOS), may also be associated with reduced
CRC risk. These compounds are potent PPAR ligands, and
have demonstrated anti-inflammatory effects in vitro [16]
and in animal studies [17] that are thought to operate via
both PPAR-dependent and –independent pathways [18].
To date, only two studies in the same cohort of fluoro-
chemical and film plant employees have assessed the asso-
ciation of PFAAs or any other PFCs to CRC: a survey study
of 1400 workers [14] and an overlapping analysis of health
claims data from 1301 employees [15]. While neither study
documented significant associations between PFOS and
CRC, conclusions were limited by very small numbers
(N = 12 confirmed CRC cases), reliance on self-report or
claims data, and lack of information on PFOS blood levels
or potential confounders.
In this study, we investigated the association of preva-
lent colorectal cancer to PFOA and PFOS in a largeAppalachian population who were exposed to elevated
levels of PFOA through contaminated drinking water.
Methods
Study population
The population for this study were adult participants in
the C8 Health Study Project [19,20], a study which re-
sulted from the settlement of a class-action lawsuit related
to the widespread PFOA contamination of drinking water
by a large production facility located in Washington, West
Virginia. PFOA production began in the 1950’s, with water
contamination first observed in the 1980’s [21]. From
August 2005 to August 2006, baseline data were gathered
on 69,030 individuals living or working in six PFOA-
contaminated water districts in Ohio and West Virginia,
including those exposed to contaminated private-well
drinking water. The first water filtration and other
abatement procedures were instituted in 2007 [21]. Project
details, including those regarding consent, enrollment, data
collection and reporting, have been published [20] and are
described online (http://publichealth.hsc.wvu.edu/c8/). In
2008, investigators in the WVU Department of Community
Medicine (now the WVU School of Public Health) were
granted formal access to the raw deidentified project data
by Brookmar, the organization responsible for conducting
the C8 health project (see http://www.hpcbd.com/C8%
20Brookmar%20Health%20Project.html), and obtained ap-
proval from the West Virginia University Institutional
Review Board to allow cleaning, coding, analysis and
publication of these data.
Estimated participation rate in the C8 Health Project
among adult residents of the affected water districts was
81% [19]. For this study, eligible participants included all
adults aged ≥21 years of age at the time of baseline as-
sessment, who had not received a diagnosis of cancer
other than colon or rectal cancer, and who had complete
data on all covariates of interest. Cases included those
with a medical-record confirmed diagnosis of colon and/
or rectal cancer. Details of sample selection are given in
below.
Outcome and exposure measurements
Participants in the C8 Health Project completed a com-
prehensive health survey and blood tests to determine
clinical biomarkers and serum levels of the primary expo-
sures of interest, PFOA, PFOS, in addition to eight other
perfluorocarbon compounds (see below) [20]. These latter
compounds included PFPeA (C5), PFHxA (C6), PFHS
(C6s), PFHpA (C7), PFNA (C9), PFDA (C10), PFUnA
(C11), and PFDoA (C12). Medical history, including phys-
ician diagnosis of medical conditions, was assessed via
self-report questionnaires. Diagnosis of cancer and cancer
type, as well as diagnoses of certain other clinical disor-
ders, including diabetes and cardiovascular disease, were
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and anthropometric characteristics were also determined
via self-report; demographic data and health survey com-
pletion were verified by trained project staff.
Laboratory methods: ascertainment of PFOA and PFOS
Blood processing, assay methods, and quality-assurance
measures are described in detail elsewhere [19,20,22].
All assay methods, assay validations, and lab procedures
were in strict adherence to Food and Drug Administration
(FDA) approved standards [23]. In brief, blood samples
were collected from each participant, serum was separated
from red cells, and the samples were immediately refriger-
ated at collection and transported on dry ice to the labora-
tory for analysis. PFAA assays used a protein precipitation
extraction method with reverse-phase high-performance
liquid chromatography/tandem mass spectrometry. De-
tection was performed using a triple quadrupole mass
spectrometer in selected reaction monitoring mode,
monitoring for the M/Z transitions of 10 individual per-
fluorocarbon compounds and an internal 13C-PFC standard
corresponding to each target compound analyzed. All la-
boratory analyses were performed using FDA bioanalytical
method validation procedures [23]. Results of all assays
were transferred automatically into the project’s Windows-
based information system to prevent transcription errors.
Of the PFCs tested, four (perfluorohexane sulfonic acid
(PFHS or C6s), PFOA (C8), PFOS (C8s), perfluoro-
nonanoic acid (PFNA or C9) were detectable in almost all
(> 97%) samples; for these compounds, test results
reported as less than the limit of detection (LOD)
were substituted with 0.25 ng/mL (50% of the lower LOD
of 0.5 ng/mL). Three PFCs (Perfluorohexanoic acid
(PFHxA or C6), perfluoroheptanoic acid (PFHpA or C7),
perfluorodecanoic acid (PFDA or C10)) were detectable in
approximately 50% of the samples; for these PFCs, no
substitutions for values were included in the analyses [20].
Statistical analysis
Data were analyzed using SPSS version 20. We used logis-
tic regression analysis to assess the independent associa-
tions of PFOA and PFOS serum levels and other factors
to CRC diagnosis, to evaluate the influence of potential
confounders, and to examine potential effect modifiers.
Linear trends were evaluated using polynomial contrasts.
Potential differences between participants with and with-
out missing data were assessed using the Students T test
or Mann–Whitney U Test (for continuous or ordinal vari-
ables) and the chi square test (for categorical variables).
The primary explanatory variables of interest, PFOA and
PFOS, were analyzed as both continuous and categorical
variables (study population quartiles and ventiles, with
the lowest percentile group used as referent category).
All p-values shown are 2-sided.Factors on which adequate data were available and which
have been previously linked to CRC and/or the two PFAAs
of interest were selected a priori as covariates. Associations
of PFAAs to CRC were initially adjusted for age, a fac-
tor strongly associated with both PFOA and PFOS levels
and CRC. Unless stated otherwise, all other multivariable
models were adjusted for age, sex, race/ethnicity, marital sta-
tus, socioeconomic status (SES, including years of education,
average family income, and employment status/disability),
participation in a regular exercise program (yes/no), vege-
tarian diet (yes/no), smoking (never, former, current),
current alcohol consumption (yes/no), menopausal status
and use of hormone replacement therapy (women), body
mass index (BMI, calculated as kg/m2), medical comorbid-
ity (reported physician diagnosis of other medical condi-
tions, including heart, kidney, liver, thyroid, immune, and
connective tissue disease, stroke, hypertension, dyslipidemia,
diabetes, chronic obstructive pulmonary disease, or asthma),
and current treatment for hypertension or hyperlipidemia.
Additional analyses adjusted for arthridides (self-reported
physician diagnosis of rheumatoid arthritis, osteoarthritis,
or fibromyalgia); gastrointestinal symptoms that could be
associated with reduced absorption (abdominal pain,
nausea, diarrhea, indigestion, and bloody stools); anemia
(hemoglobin < 12 g/dL in women and <13.5 g/dL in men);
and serum levels of folate (ng/mL), cholesterol (mg/dL),
C-reactive protein (mg/L), uric acid (mg/dL), estradiol
(pg/mL), and other PFAAs measured in the C8 Health
Project.
To evaluate potential modifying effects of gender, BMI
(<30, ≥30), treatment method (chemotherapy/radiation
vs. no chemotherapy/radiation), and years since diagnosis
(before 2000 vs. 2000 or later) on the association of PFAA
levels (in quartiles) to history of CRC, we conducted multi-
variable analyses stratified by each potential effect modifier.
We tested the strength of each interaction by including
the corresponding multiplicative interaction term in
the main adjusted statistical model and evaluating the
coefficient using the Wald test. In addition, to assess
the robustness of the observed associations, we con-
ducted additional sensitivity analyses to evaluate the
relation of CRC diagnosis to PFOA and PFOS at differing
levels of exposure and to assess the relation of recently di-
agnosed CRC to these PFAAs in participants who were
long term residents of the affected water districts. To
help assess whether observed associations of PFOA and/
or PFOS could be due reverse causality (e.g., reduced
absorption), we conducted additional analyses adjusting
for anemia and specific GI symptoms (frequent diarrhea,
bloody stool, abdominal pain, nausea, and/or constipation)
as well as analyses excluding CRC cases who were cur-
rently under treatment or had received chemotherapy. We
also assessed the association of CRC prevalence to other
gut-absorbed compounds, including folate and other PFCs
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C7, C9, and C10).
Results
The study flow diagram is given in Figure 1. Participants
who had received a diagnosis of cancer other than pri-
mary colon or rectal cancer (N = 4116) were excluded
from the analytic sample, leaving a total of 49,312 eli-
gible adults. Exclusion of participants with missing data
on PFOA and PFOS (N = 296, 0.6%) and other covariates
of interest (N = 1584, 3.2%) and of colorectal cancer
cases that could not be validated due to missing infor-
mation (N = 73) yielded a final study sample of 47,359,
including 47,151 cancer-free controls and 208 adults
with a medical record-confirmed diagnosis of primary
colon or rectal cancer. Among validated CRC cases with
information on diagnosis date (N = 193), 99 were diag-
nosed prior to 2000, and 94 received a diagnosis in 2000
or later (median 1999, range 1966 to 2006). Compared
to participants included in the analyses, those with miss-
ing data on any covariate were more likely to be female
and postmenopausal, to be older, less educated and
heavier, and to report lower income and higher preva-
lence of comorbid medical conditions (P < 0.01).
The distribution of study population characteristics by
CRC diagnosis is given in Table 1. Participants ranged in
age from 21 to 105 years of age (mean (SD) = 45.71 (15.0)Figure 1 Study flow diagram.years), and were predominantly (97%) non-Hispanic white.
Fifty-two percent were female, 38% reported an annual
household income of less than $30,000, and 53% had re-
ceived only 12 years of schooling or less. Sixty-three per-
cent were employed, and 7% were disabled. Over 70% of
the adults in this Appalachian population were overweight
(BMI 25 or greater), and over 35% were obese (BMI ≥30).
Of the 47,359 eligible participants with no missing data,
208 were diagnosed with CRC. After adjustment for all
other factors in the table, CRC retained significant, posi-
tive associations with age (p < 0.00001) and male gen-
der (p < 0.05), and with postmenopausal status in women
(P <0.003). Participants who were disabled or had been di-
agnosed with at least one chronic medical condition were
also significantly more likely to have been diagnosed with
CRC (P < 0.02). Conversely, those who were on lipid-
lowering medications were less likely to have received a
diagnosis of CRC (P <0.02).
Serum values of PFOA were elevated in this population,
averaging 86.6 (255.1) ng/mL (median = 27.9, range <0.5-
22,412 ng/mL), compared to a geometric mean of 3.7-
4.2 ng/mL across adult age ranges in the 2003–2004
NHANES population [24]. In contrast, PFOS serum levels
in our study sample were similar to those in the general
U.S. population [24], ranging from <0.5 to 759.2 ng/mL
and averaging 23.4 ± 16.3 ng/mL (median = 20.2 ng/mL).
Likewise, serum levels of other PFAA’s for which ad-
equate data were available were comparable to general
background levels in the U.S [24,25].
Table 2 details the associations between CRC diagnosis
and serum levels of PFOA and PFOS. PFOS showed a
strong, inverse association to diagnosis of CRC in both the
minimally adjusted analysis and the full models. Those
testing in the highest PFOS quartile were 80% less likely
to have been diagnosed with CRC than those in the lowest
quartile (odds ratio (OR) = 0.2, 95% confidence interval
(CI) 0.1, 0.3, P for trend < 0.00001) after adjustment for
age and BMI. Further adjustment for sociodemographic
characteristics, menopausal status and hormone replace-
ment therapy (HRT) use, lifestyle factors, and comorbidity
did not materially alter these risk estimates (OR’s = 0.35
(CI 0.2, 0.5), 0.3 (CI 0.2, 0.5), and 0.2 (CI 0.2, 0.3) for the
second, third, and highest quartile of PFOS, respectively;
P for trend < 0.00001), nor did additional adjustment for
gastrointestinal (GI) symptoms and for serum levels of fol-
ate, estradiol, cholesterol, uric acid, and C-reactive protein.
The association of CRC to serum PFOS analyzed as a con-
tinuous variable showed a similar pattern, with the strength
of the linear relationship remaining constant after adjust-
ment for other demographic, lifestyle, and health-related
factors (P < 0.00001, Table 2).
PFOA also demonstrated a significant, inverse, although
more modest relationship to CRC (Table 2). Participants
in the highest PFOA quartile showed an approximately
Table 1 Characteristics of adults ≥ 21 years of age from 6 PFOA-contaminated water districts in the Ohio Valley,
stratified by diagnosis of colorectal cancer (N=208 colorectal cancer cases, 47,151 cancer-free controls)
Diagnosis of colorectal cancer
Adjusted OR**
(95% CI) P-value*
No (N=47,151) Yes (N=208)
N % N %
Demographic characteristics
Age (Years) <0.00001
Mean (SD) 45.49 (14.97) 67.92 (10.80)
Per year increment 1.10 (1.07,1.11) <0.00001
Gender 0.05
Female 24292 51.52% 94 45.19% 1.00 (Referent)
Male 22859 48.48% 114 54.81% 1.40 (1.00,1.57)
Ethnicity 0.12
White 45835 97.33% 207 99.52% 1.00 (Referent)
Minority 1256 2.67% 1 0.48% 0.21 (0.03,1.51)
Marital status 0.53
Married/co-habiting 34170 72.47% 157 75.48% 1.00 (Referent)
Single 6105 12.95% 6 2.88% 0.81 (0.35,1.88)
Divorced/separated 5145 10.91% 14 6.73% 0.83 (0.47,1.47)
Widowed 1731 3.67% 31 14.90% 0.72 (0.46,1.15)
Years of education .
<12 years 5102 10.82% 50 24.04% 1.00 (Referent) 0.85
High school/GED 19674 41.73% 91 43.75% 0.89 (0.60,1.31)
Some college 15777 33.46% 51 24.52% 0.97 (0.60,1.55)
4+ years college 6598 13.99% 16 7.69% 0.79 (0.40,1.54)
Current employment status 0.29
Employed 29704 63.53% 42 20.19% 1.00 (Referent)
Homemaker 5411 11.57% 30 14.42% 1.53 (0.88,2.68)
Retired 5679 12.15% 115 55.29% 1.75 (1.10,2.77)
Unemployed/Laid off 1992 4.26% 3 1.44% 1.83 (0.56,5.97)
Student 833 1.78% 0 0.00% 0.00 (0.00,0.00)
Disabled 3132 6.70% 17 8.17% 1.94 (1.06,3.57)
Other 4 0.01% 1 0.48% 1.20 (0.16,9.09)
Average household income 0.49
≥ $30, 000 25269 53.59% 88 42.31% 1.00 (Referent)
< $30, 000 17635 37.40% 103 49.52% 1.05 (0.78,1.41)
Don’t know 4247 9.01% 17 8.17% 1.07 (0.70,1.63)
Ever consumed alcohol 0.46
No 23348 49.52% 91 43.75% 1.00 (Referent)
Yes 23803 50.48% 117 56.25% 1.08 (0.83,1.47)
Smoking status 0.06
Never 22305 47.31% 101 48.56% 1.00 (Referent)
Former 12298 26.08% 91 43.75% 1.04 (0.76,1.43)
Current 12548 26.61% 16 7.69% 0.51 (0.29,0.89)
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Table 1 Characteristics of adults ≥ 21 years of age from 6 PFOA-contaminated water districts in the Ohio Valley,
stratified by diagnosis of colorectal cancer (N=208 colorectal cancer cases, 47,151 cancer-free controls) (Continued)
Regular exercise program 0.59
No 32512 68.95% 139 66.83% 1.00 (Referent)
Yes 14639 31.05% 69 33.17% 0.96 (0.73,1.26)
Vegetarian diet 0.53
No 46802 99.26% 205 98.56% 1.00 (Referent)
Yes 349 0.74% 3 1.44% 1.46 (0.53,4.68)
Anthropometrics and medical history
BMI (kg/m2) 0.47
< 24.99 13698 29.10% 51 24.52% 1.00 (Referent)
25-29.99 16600 35.27% 91 43.75% 1.32 (0.93,1.89)
30-34.99 9912 21.06% 42 20.19% 1.19 (0.78,1.83)
≥ 35 6859 14.57% 24 11.54% 1.33 (0.79,2.25)
Per unit increment BMI 1.02 (0.99,1.04) 0.21
Mean (SD) 28.80 (6.40) 28.35 (5.82)
Comorbid condition(s)ŧ 0.005
No 30299 64.26% 71 34.13% 1.00 (Referent)
Yes 16852 35.74% 137 65.87% 1.56 (1.14,2.13)
On lipid-lowering medication 0.03
No 31949 67.76% 132 63.46% 1.00 (Referent)
Yes 15202 32.24% 76 36.54% 0.72 (0.52,0.97)
On anti-hypertensive medication 0.29
No 34990 74.21% 103 49.52% 1.00 (Referent)
Yes 12161 25.79% 105 50.48% 0.79 (0.58,1.07)
Reproductive history (women, N=24292 controls, 94 cases)
Postmenopause 0.003
No 14361 59.12% 4 4.26% 1.00 (Referent)
Yes 8935 36.78% 88 93.62% 7.64 (2.35,24.79)
Don’t know 996 4.10% 2 2.13% 3.93 (0.70,22.06)
History of hormone replacement therapy 0.08
No 16973 69.87% 57 60.64% 1.00 (Referent)
Yes 7319 30.13% 37 39.36% 0.66 (0.42,1.05)
*All p-values are 2-sided **Adjusted for other factors in table.
ŧReported physician diagnosis of other medical conditions, including heart, kidney, liver, thyroid, immune, and connective tissue disease, stroke, hypertension,
dyslipidemia, diabetes, chronic obstructive pulmonary disease, or asthma.
Abbreviations: BMI Body mass index, CI Confidence intervals, PFOA perfluorooctanoate, OR Odds ratio, SD Standard deviation.
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OR = 0.6, CI 0.4, 0.9, P for trend = 0.002), although
the linear trend was weak and non-significant when
PFOA was analyzed as a continuous variable (p = 0.42).
Additional adjustment for other demographic, socio-
economic, lifestyle, and health-related factors did not
appreciably alter the strength or magnitude of this inverse
association.
Further adjustment for other PFAAs, for anemia, or
for diagnosed osteoarthritis, rheumatoid arthritis, and
fibromyalgia or did not alter these associations, nor didexclusion of those with low hemoglobin levels (N = 2391,
including 41 CRC cases).
As detailed in Tables 3, 4 and 5, the protective associ-
ation of PFOA was more pronounced in men than in
women (age-adjusted OR’s, respectively for the highest
vs. the lowest quartile = 0.5 (CI 0.3, 0.9) vs. 0.8 (CI 0.4,
1.3), p for interaction < 0.05) and tended to be stronger
in leaner (BMI < 30) than in obese adults (BMI 30+)
(fully adjusted OR’s, respectively, for highest vs. lowest
quartile = 0.5 (CI 0.3, 0.9) vs. 0.9 (CI 0.5, 1.8), p for inter-
action < 0.09). Similarly, the inverse relation of PFOA to
Table 2 Association of serum perfluorooctanoate (PFOA) and perfluorooctane sulfonic acid (PFOS) levels to colorectal cancer diagnosis (N=208 colorectal
cancer cases, 47,151 cancer free controls) in adults aged 21 and older
CRC
cases (N)
Controls (N) Adjusted for age Adjusted for age, race, gender, SES, marital
status, lifestyle factors*, BMI, menopausal
status, and comorbidityŧ
Also adjusted for metabolic/physiologic
profile** and gastrointestinal symptoms¥
Odds
ratio
95% CI P Odds
ratio
95% CI P Odds
ratio
95% CI P
Lower Upper Lower Upper Lower Upper
PFOS quartiles
First (0.25-13.5 ng/mL) 79 11657 1.00 Referent 1.00 Referent 1.00 Referent
Second (13.6-20.1 ng/mL) 39 11788 0.39 0.26 0.57 <0.00001 0.35 0.24 0.53 <0.00001 0.38 0.25 0.59 <0.00001
Third (20.2-29.1 ng/mL) 42 11838 0.33 0.23 0.48 <0.00001 0.30 0.20 0.45 <0.00001 0.27 0.17 0.42 <0.00001
Fourth (≥ 29.2 ng/mL) 48 11868 0.27 0.19 0.39 <0.00001 0.23 0.15 0.34 <0.00001 0.24 0.16 0.37 <0.00001
Test for trend <0.00001 <0.00001 <0.00001
Per unit increase PFOS (ng/mL) 0.97 0.96 0.98 <0.00001 0.96 0.95 0.97 <0.00001 0.96 0.95 0.97 <0.00001
PFOA quartiles
First (0.25-13.4 ng/mL) 58 11588 1.00 Referent 1.00 Referent 1.00 Referent
Second (13.5-27.8 ng/mL) 36 11988 0.50 0.33 0.77 0.001 0.47 0.31 0.74 0.001 0.48 0.31 0.75 0.001
Third (27.9-71.2 ng/mL) 49 11796 0.53 0.36 0.78 0.001 0.49 0.33 0.74 0.001 0.51 0.34 0.77 0.001
Fourth (≥ 71.3 ng/mL) 65 11779 0.64 0.45 0.92 0.02 0.61 0.42 0.89 0.01 0.64 0.44 0.94 0.02
Test for trend 0.002 0.001 0.002
Per unit increase PFOA (ng/mL) 1.00 1.00 1.00 0.42 1.00 1.00 1.00 0.35 1.00 1.00 1.00 0.46
Abbreviations: BMI body mass index (kg/m2), CI Confidence interval, CRP C-reactive protein, HRT hormone replacement therapy, SES socioeconomic status.
*Lifestyle factors include smoking (never, former, current); current alcohol consumption (yes/no); vegetarian diet (yes/no); exercise (regular exercise program (yes/no)); SES includes years of education, annual
household income, and employment status/disability.
ŧComorbidity includes physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, and thyroid disease, stroke, hypertension, dyslipidemia, diabetes, chronic obstructive pulmonary
disease, or asthma) and current treatment for hypertension or hyperlipidemia.
**Serum lipid profiles, C-reactive protein, estradiol, and uric acid.

















Table 3 Association of serum PFOS and PFOA levels to CRC diagnosis by gender in adults ≥ 21 years of age*
Men only (N=114 cases) Women only (N=94 cases) P for
interactionCases Controls Odds
ratio
95% CI P Cases Controls Odds
ratio
95% CI P
Lower Upper Lower Upper
PFOS quartiles
First (reference) 54 5645 1.00 32 6002 1.00 0.30
Second 18 5743 0.34 0.20 0.59 0.00001 19 6122 0.38 0.21 0.67 0.001
Third 20 5708 0.28 0.17 0.47 <0.00001 19 6065 0.32 0.18 0.57 0.0001
Fourth 22 5763 0.20 0.12 0.34 <0.00001 24 6103 0.31 0.18 0.53 0.00002
Test for trend <0.00001 <0.00001
PFOA quartiles
First (reference) 39 5665 1.00 22 5997 1.00 0.04
Second 18 5761 0.35 0.19 0.64 0.001 23 6130 0.70 0.38 1.26 0.23
Third 27 5719 0.49 0.29 0.81 0.006 21 6096 0.56 0.31 1.02 0.06
Fourth 30 5714 0.53 0.32 0.86 0.01 28 6069 0.76 0.44 1.32 0.33
Test for trend 0.002 0.32
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http://www.biomedcentral.com/1471-2407/14/45prevalent CRC was significantly stronger in those diagnosed
within the previous 6 years (2000 or later) relative to those
diagnosed earlier (adjusted OR’s, respectively for the highest
vs. the lowest quartile = 0.4 (CI 0.3, 0.7) vs. 0.9 (CI 0.5, 1.6)).
The association of PFOS to likelihood of CRC was also more
pronounced in those diagnosed more recently (adjusted
OR’s, respectively, for highest vs. lowest quartile = 0.1
(CI 0.1, 0.2) vs. 0.4 (CI 0.3, 0.7)) (Table 5). We did not find
evidence for a modifying effect of gender or BMI on the re-
lation of CRC to PFOS, or of age or CRC treatment method
on the association of CRC to either PFOA or PFOS.
Similarly, as illustrated in Table 6, restricting the ana-
lysis to those who had lived at the same residence since
1990–1995 or before and to CRC cases diagnosed in 2000Table 4 Association of serum PFOS and PFOA levels to CRC dia






First (reference) 26 4144 1.00
Second 11 4240 0.26 0.13 0.55 0.0004
Third 14 4194 0.30 0.16 0.58 0.0004
Fourth 15 4209 0.23 0.12 0.44 <0.00001
Test for trend <0.00001
PFOA quartiles
First (reference) 18 4166 1.00
Second 13 4226 0.62 0.29 1.32 0.22
Third 16 4200 0.69 0.34 1.39 0.30
Fourth 19 4195 0.87 0.45 1.67 0.67
Test for trend 0.57or later strengthened the inverse associations with both
PFAAs. Adjusted OR’s for highest vs. lowest quartile were
0.1 (CI 0.1, 0.2) for PFOS and 0.4 (CI 0.2, 0.5) for PFOA.
Further restricting CRC cases to those diagnosed in 2005–
6 (N = 15 CRC cases) yielded similar findings (adjusted
OR’s for highest vs. lowest quartile = 0.1 (CI 0.0, 0.5) for
PFOS and 0.4 (CI 0.1, 1.4) for PFOA).
Sensitivity analyses
To determine whether the observed positive association
of PFOA to CRC differed at exposure levels more typical
of non-contaminated areas, we limited our subanalysis
to adults with serum concentrations of PFOA ≤ 20 ng/mL
(N = 19,201 adults, including 84 with CRC), with thegnosis in adults ≥ 21 years of age, stratifed by BMI*





52 7496 1.00 0.65
30 7673 0.42 0.26 0.67 0.0002
27 7531 0.30 0.19 0.49 <0.00001
33 7664 0.25 0.16 0.39 <0.00001
<0.00001
43 7575 1.00 0.09
24 7594 0.44 0.26 0.73 0.002
35 7608 0.45 0.28 0.72 0.001
40 7587 0.52 0.34 0.80 0.003
0.001
Table 5 Association of serum PFOA and PFOS levels to CRC diagnosis in adults 21+years, stratified by year of
diagnosis*
Diagnosis in 2000 or later (N=94 cases)** Diagnosis before 2000 (N=99 cases)** P for
interactionCases Controls Odds
ratio
95% CI P Cases Controls Odds
ratio
95% CI P
Lower Upper Lower Upper
PFOS quartiles
First (reference) 50 11657 1.00 27 11657 1.00 0.04
Second 15 11788 0.22 0.12 0.39 <0.00001 20 11788 0.56 0.31 1.00 0.05
Third 16 11838 0.18 0.10 0.31 <0.00001 23 11838 0.49 0.28 0.87 0.015
Fourth 13 11868 0.10 0.05 0.19 <0.00001 29 11868 0.44 0.25 0.74 0.002
Test for trend <0.00001 0.015
PFOA quartiles 0.02
First (reference) 35 11588 1.00 21 11588 1.00
Second 14 11988 0.32 0.17 0.59 0.0003 18 11988 0.68 0.36 1.27 0.23
Third 19 11796 0.34 0.19 0.59 0.0002 25 11796 0.71 0.39 1.28 0.26
Fourth 26 11779 0.41 0.25 0.68 0.0007 35 11779 0.91 0.53 1.58 0.74
Test for trend 0.00004 0.50
Table 3-5. Abbreviations: BMI body mass index (kg/m2), CI Confidence interval, CRC colorectal cancer, PFOA perfluorooctanoate, PFOS perfluorooctane sulfonic acid.
*All analyses adjusted for sociodemographic and lifestyle factors, BMI, menopausal status, and comorbidity. Sociodemographics include age, race/ethnicity,
gender, education, income, marital status, and employment status; lifestyle factors include smoking status; current alcohol consumption; regular exercise program;
comorbidity includes physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, and thyroid disease, stroke, hypertension,
dyslipidemia, diabetes, chronic obstructive pulmonary disease, or asthma) and current treatment for hypertension or hyperlipidemia.
**Information on year of diagnosis missing for 15 CRC cases.
Table 6 Association of serum perfluorooctanoate (PFOA) and perfluorooctane sulfonic acid (PFOS) levels to colorectal
cancer diagnosis in adults aged 21 and older, by year of diagnosis and period of residence in affected water district
Resident since 1995 or before and including only CRC cases
diagnosed 2000 or later (N=21,233 controls, 71 CRC cases)
Resident since 1990 or before and including only CRC cases
diagnosed 2000 or later (N=15,533 controls, 60 CRC cases)
Cases Controls Odds ratio
(95% CI)*




First 42 5278 1.00 37 3884 1.00
Second 12 5312 0.19 (0.09,0.38) <0.00001 9 3884 0.18 (0.08,0.40) 0.00002
Third 7 5322 0.13 (0.06,0.27) <0.00001 7 3864 0.14 (0.06,0.30) <0.00001
Fourth 10 5321 0.12 (0.06,0.23) <0.00001 7 3901 0.12 (0.06,0.24) <0.00001
Test for trend <0.00001 <0.00001
PFOA quartiles
First 28 5284 1.00 25 3870 1.00
Second 7 5325 0.25 (0.11,0.55) 0.001 9 3921 0.24 (0.10,0.56) 0.001
Third 21 5313 0.37 (0.19,0.70) 0.002 13 3828 0.32 (0.16,0.66) 0.002
Fourth 15 5311 0.43 (0.24,0.78) 0.005 13 3914 0.38 (0.20,0.72) 0.003
Test for trend 0.001 0.001
*Odds ratios adjusted for age, race, gender, socioeconomic status (years of education, annual household income, and employment status/disability), marital status,
lifestyle factors, BMI, menopausal status, and comorbidity. Lifestyle factors include smoking (never, former, current); current alcohol consumption (yes/no);
vegetarian diet (yes/no); exercise (regular exercise program (yes/no); comorbidity includes physician diagnosis of chronic comorbid condition (heart, kidney, liver,
immune, connective tissue, and thyroid disease, stroke, hypertension, dyslipidemia, diabetes, chronic obstructive pulmonary disease, or asthma) and current
treatment for hypertension or hyperlipidemia.





Figure 2 Association of serum PFOA and PFOS levels to likelihood of colorectal cancer diagnosis. a. All eligible participants (N=208 CRC
cases, 47,151 controls). b. Sample restricted to those with PFOA serum values ≤ 20 ng/mL (N=84 CRC cases, 19,117 controls). c. All eligible participants
(N=208 CRC cases, 47,151 controls). d. Sample restricted to those with PFOS serum values ≤ 20 ng/mL (N=118 CRC Cases, 23,287 Controls).
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http://www.biomedcentral.com/1471-2407/14/45lowest quartile (referent group) comprising blood levels
similar to those in the U.S. general population [24]. Restrict-
ing the analysis to adults with these relatively low levels of
exposure substantially strengthened the linear, inverse
relationship of PFOA to CRC diagnosis, suggesting a
possible threshold effect (age-adjusted OR for the highest
vs. lowest quartile = 0.4 (CI 0.2, 0.7), p for trend =0.009).
In this lower-exposure group, PFOA also showed a signifi-
cant, linear association with CRC diagnosis when analyzed
as a continuous variable (fully adjusted P = 0.001). Simi-
larly, while the negative association of CRC to PFOA
levels, in ventiles, did not appear linear in the overall popu-
lation, a modest linear trend was evident among adults
with PFOA levels ≤20 ng/mL, with likelihood of CRC diag-
nosis declining with increasing PFOA serum percentile rela-
tive to the lowest percentile range (5th percentile, ≤ 3.8
ng/mL) (Figure 2a, b). Using the contemporaneous U.S.
population mean for PFOA (NHANES, 2003-4 [24]) as
the referent category yielded similar results. In contrast,
the probability of CRC diagnosis declined strongly withincreasing PFOS serum percentile in both the overall
population and in the restricted analyses (Figure 2c, d).
Removal of primary rectal cancer cases (N = 29) from
the analysis did not alter the observed associations with
either PFOA or PFOS. Similarly, removal of those who
reported undergoing current treatment (N = 21) did not
attenuate the findings (fully adjusted OR’s for the highest
vs. the lowest quartile for PFOS and PFOA, respectively =
0.2 (CI 0.1, 0.3), p for trend < 0.00001; and 0.6 (0.4, 0.95),
p for trend < 0.001), nor did removal of those who had re-
ceived chemotherapy (N = 109). Main analyses were also
repeated in all participants reporting a physician diagnosis
of primary colorectal cancer (N = 281); inclusion of these
additional unconfirmed cases did not appreciably change
either the strength or the magnitude of the observed asso-
ciations (fully adjusted OR’s for the highest vs. the lowest
quartile for PFOS and PFOA, respectively = 0.2 (CI 0.2,
0.3), p for trend < 0.00001; and 0.6 (0.4, 0.9), p for trend
< 0.01). In contrast, another gut-absorbed compound, fol-
ate, showed no relation to CRC diagnosis (p = 0.68), and
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status (p > 0.4). Associations of CRC to the 5 additional
PFCs were inconsistent, with 2 (C6, C10) showing signifi-
cant positive associations (p < 0.001), 2 (C6s, C9) showing
significant inverse associations (p ≤ 0.01), and one (C7)
showing no association (p = 0.7) with CRC.
Discussion
To our knowledge, this is the first large, community-
based study to examine the potential links between CRC
and environmental PFAAs, and the first to examine in
detail the association of CRC to PFOA and PFOS. Our
findings indicate a significant inverse association between
both PFOS and PFOA and diagnosis of CRC in this large
cross-sectional study. This association between PFOS and
CRC was particularly pronounced, with a strong linear in-
verse relationship that remained robust even at lower ex-
posure levels. After adjustment for multiple potential
confounders, those with serum PFOS levels in the highest
quartile were approximately 80% less likely to have re-
ceived a diagnosis of CRC; likewise, those in the highest
quartile of PFOA were approximately 40% less likely to
have been diagnosed with CRC. These inverse associations
were stronger with CRC diagnosed within the previous
6 years and in long term residents of the affected water
districts. The relationship between PFOA and CRC was
also more pronounced in men and leaner adults, and
showed a strong linear trend only at lower serum concen-
trations comparable to those observed in the general US
general population, suggesting a possible threshold or sat-
uration effect for this PFAA.
Experimental studies have indicated carcinogenic effects
of both PFOA and PFOS in rodent models, at least at high
exposures; however, no associations between these PFAA’s
and CRC have been reported. Moreover, published studies
regarding potential links between PFAAs and cancer in
humans are sparse and have yielded inconclusive findings.
Two European studies, including a large Danish nested
cohort study (N = 1240 liver, bladder, pancreatic, and pros-
tate cancer patients) [26] and a small Greek case–control
study (N = 40 cancer patients) [27], reported no associa-
tions between serum levels of either PFAA and cancer
diagnosis. While two previous investigations in a co-
hort of PFOS-exposed workers suggested a possible
positive relation between high PFOS exposure and
CRC, the findings were non-significant, based on very
small case numbers, and reliant on indirect measures
of exposure [14,15].
Consistent with previous studies, we found the likelihood
of CRC diagnosis to increase strongly with age [2]. Meno-
pause was also positively associated with CRC diagnosis, in
agreement with findings of some [28-31] but not other in-
vestigations [32-34]. Likewise, those on lipid-lowering med-
ications were also less likely to have been diagnosed withCRC, similar to findings from some [35-37], but not all
studies [38-41]. In this study, those with comorbid condi-
tions were more likely to have received a diagnosis of
CRC. Previous studies have shown comorbidity to predict
earlier stage of CRC diagnosis [42] as well as reduced sur-
vival in CRC patients [43]. Several but not all [44] studies
have reported increased CRC risk in association with spe-
cific conditions, including hypertension, [45,46] diabetes
[45-47], and other chronic disorders [45,46], although re-
search specifically assessing the association between over-
all comorbidity and diagnosed CRC is sparse. BMI was
unrelated to CRC diagnosis overall in the current study
after adjustment for other sociodemographic and medical
factors. However, stratification by gender revealed BMI to
be significantly associated with CRC in men but not in
women (adjusted ORs for BMI ≥ 25 in men vs. women, re-
spectively = 1.9 (CI 1.1, 3.2) vs. 1.0 (0.6, 1.5), p for inter-
action = 0.01), findings consistent with those of previous
investigations [48].
The strengths of the study include the population-
based design, the large sample size, and the high study
participation rates in an Appalachian region. Additional
strengths include our ability to evaluate persistent bio-
markers of PFAA exposure obtained concurrently with
survey and medical record information regarding CRC
and other chronic conditions, the measurement of a broad
array of biomarkers, and the extensive information available
on potential confounders and effect modifiers. Ascertain-
ment of CRC was based on participant-reported physician
diagnosis and confirmed by chart review. We were also able
to assess the association of CRC to PFOA and PFOS over a
wide range of serum concentrations, helping to clarify the
possible modifying effects of exposure level.
Our study has several important limitations as well.
While human half-lives of PFOA and PFOS are long (up
to 8.5 [49] and 5.4 years [50], respectively), random mis-
classification error due to the use of current PFC levels
as proxy measures of etiologically relevant exposures
may have biased our results toward the null. Most im-
portantly, the cross-sectional nature of the data limits
our ability to determine direction of causality. However,
the persistence of PFOA and PFOS in human tissues,
coupled with the strong inverse associations observed
with recent CRC diagnosis in long-term residents, and
the robust inverse association of both PFOA and espe-
cially, PFOS to CRC at varying exposure levels suggest
that a causal relationship may be plausible. While it re-
mains possible that differences in absorption due to the
disease or treatment could help explain the observed ef-
fects, several lines of reasoning suggest this may not be
the case. Adjustment for anemia and for GI symptoms
potentially related to reduced absorption did not alter
the observed associations, nor did removal of those cur-
rently on treatment or who had received chemotherapy.
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ileum, folate, showed no relation to CRC diagnosis, and
age-adjusted serum folate levels did not differ by disease
status. Moreover, the associations of prevalent CRC to
serum levels of other PFCs were inconsistent, with 3 of
the 5 appearing unrelated or positively related to CRC
diagnosis. In addition, CRC has been characterized by
reduced gut motility and over-efficient enterohepatic cir-
culation [51], which would be expected to lead to in-
creased, rather than reduced PFAA serum levels [52-54].
Nonetheless, while these observations collectively sug-
gest that altered PFAA absorption due to CRC and CRC
treatment is unlikely to explain the robust inverse asso-
ciations observed in this study, reverse causality remains
a possibility and caution is thus warranted in interpret-
ing our findings.
Additional limitations include lack of information on
CRC stage at diagnosis and on certain risk factors for
CRC, including inherited genetic alterations, history of
inflammatory bowel disease, and specific dietary factors.
As only self-reported physician diagnoses of CRC and
other cancers were confirmed by chart review, unascer-
tainment due to under-reporting remains possible. How-
ever, such underascertainment would be expected to
bias the observed associations toward the null, and thus
is unlikely to explain our findings. Exclusion of eligible
participants with missing data on covariates may have
introduced selection bias. Fortunately, the percentage
with missing data was small (3.8%). Moreover, given
those with missing data did not differ in either their PFC
levels or in the incidence of CRC, their exclusion would
not be expected to alter the observed associations. Diag-
nosis could not be validated for a substantial portion
(25.8%) of those reporting a physician diagnosis of CRC.
However, inclusion of both validated and non-validated
cases in the analysis did not alter our findings. Diagnosis
was also verified for 100% of participants who reported
primary CRC and for whom information was available,
indicating excellent reliability and validity of self report
diagnosis in this study sample.
Although considerable efforts were made to contact
former residents of affected counties, some otherwise
eligible adults who moved out of the area may not have
participated in the study, possibly introducing sampling
bias. Our study population did not include those who
had died from CRC and thus may not be representative of
adults with more aggressive or advanced disease, limiting
generalizability. However, the relation of both PFAAs to
CRC diagnosis was stronger in those diagnosed more re-
cently, and remained robust even in those diagnosed
within a year of study health assessment, suggesting that
survival bias is unlikely to account for our findings. Un-
measured confounding might also help explain our find-
ings, although our ability to control for a large number ofboth known and potential risk factors for CRC renders this
possibility less probable. Finally, some degree of method
uncertainty in PFC detection is also possible. However,
such uncertainty would be expected to attenuate observed
associations and is thus unlikely to explain our findings. In
addition, that the laboratory performing the assays
followed U.S. Food and Drug Administration (FDA) ap-
proved procedures, and assays met the FDA standard for
assay precision suggest that significant method uncertainty
is unlikely.
If the association with either PFAA proves causal, possible
physiologic explanations may include immune modulation,
specific anti-cancer effects, including anti-proliferative, apop-
totic and differentiating effects, and physiological changes
related to the chemical properties of these PFAAs. While
animal studies have yielded somewhat inconsistent results
[17,55], a number of investigations in both rodent models
and human cell lines suggest PFOA and PFOS can have
potent anti-inflammatory effects. For example, in mouse
models of inflammation, oral administration of PFOS in
doses comparable to those reported in exposed human
populations significantly reduced serum TNF-α and de-
creased peritoneal lavage fluid TNF-α and interleukin-6
levels in response to an immune challenge [17]. Similarly,
relatively low doses of PFOA were found to dramatically
reduce multiple signs of peripheral inflammation in
rats, an effect that did not appear mediated by gluco-
corticoid receptors [56]. Consistent with these findings,
recent in vitro studies of human leukocytes showed PFOS
to decrease release of TNF-α following lipopolysaccharide
stimulation [57].
The observed anti-inflammatory effects of these PFAAs
may be mediated in part by activation of peroxisome
proliferator-activated receptors (PPARs). PPARs are tran-
scription factors that belong to the superfamily of nuclear
receptors whose natural activating ligands are lipid-derived
substrates. A growing body of experimental evidence sug-
gests PFOA and PFOS are potent PPAR ligands, acting as
agonists for both the alpha (PPAR-α) and gamma isotypes
(PPAR-γ) [17,18,58-60]. PPARs are expressed on macro-
phages [61], and are highly expressed in intestinal [59] and
other tissues [18]. These receptors are now thought to play
a major role in the regulation of inflammatory responses
[11,18,62-64]. For example, PPAR-γ has been shown to
down-regulate the expression of inflammatory cytokines, in-
hibit major inflammatory signaling pathways [65], and direct
immune cell differentiation towards anti-inflammatory phe-
notypes [66].
PPARs are also thought to play a key role in the differ-
entiation, apoptosis and proliferation of colon and other
tumor cells [10,11,63], contributing to the growing re-
search interest in these receptors and their ligands as
potential chemoprevention and chemotherapeutic agents
[10,11]. Studies in rodent models of colorectal and other
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have shown PPAR-γ ligands to exert powerful anti-cancer
effects; these effects appear mediated by the differentiat-
ing, pro-apoptotic, and anti-proliferative effects on malig-
nant cells, as well as by the anti-inflammatory actions of
PPAR-γ [10,11]. Likewise, PPAR-α has also been impli-
cated in the inception and progression of CRC. For ex-
ample, PPAR-α ligands induce apoptosis in human tumor
cell lines and PPAR-α expression is reduced in human
tubular adenomas and colonic adenocarinoma cells com-
pared to normal human colonic mucosa [63,67]. In addition,
both PPAR-α and PPAR-γ ligands have been shown to sup-
press polyp formation in an animal model of familial polyp-
osis [67,68].
Finally, PFOS and PFOA are also surfactants, character-
ized by strong hydrophobic properties [69], which could,
in turn, contribute to a protective effect against CRC.
While this possibility remains unexplored in PFAAs, other
compounds with hydrophobic properties have been shown
to induce cell cycle arrest and apoptosis of human colon
cancer [70] and other tumor cells [71].
Conclusions
In this cross-sectional study of a large Appalachian
population, we found a strong inverse linear association
between PFOS and likelihood of CRC diagnosis and a sig-
nificant, although more modest inverse association between
PFOA and diagnosis of CRC. If confirmed in prospective
investigations, these findings could aid in identifying new
strategies for CRC prevention and treatment and help in-
form future studies regarding possible mechanisms under-
lying the pathogenesis of this of this common and often
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